Cargando…

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

BACKGROUND: Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin’s efficacy and safety in everyday clinical practice with special...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sirvén, Milana Bergamino, Fernández-Ortega, Adela, Stradella, Agostina, Morilla, Idoia, Falo, Catalina, Vázquez, Silvia, Castany, Roser, Villanueva, Rafael, Recalde, Sabela, Pérez, Valentí Navarro, Gil-Gil, Miguel, Pernas, Sonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868802/ https://www.ncbi.nlm.nih.gov/pubmed/31753013 http://dx.doi.org/10.1186/s40360-019-0367-x

Ejemplares similares

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
por: Gil-Gil, Miguel J., et al.
Publicado: (2021)

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
por: Lutrino, Eufemia S., et al.
Publicado: (2019)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
por: Zhao, Yannan, et al.
Publicado: (2021)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies
por: Rossi, Sabrina, et al.
Publicado: (2017)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
por: Gui, Xinyu, et al.
Publicado: (2023)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

In vitro radiosensitization by eribulin in human cancer cell lines
por: Benlloch, Raquel, et al.
Publicado: (2022)

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance
por: Ruiz de Garibay, Gorka, et al.
Publicado: (2018)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells
por: Bellio, Chiara, et al.
Publicado: (2022)

Immune Cell Associations with Cancer Risk
por: Palomero, Luis, et al.
Publicado: (2020)

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer
por: Lopez-Bonet, Eugeni, et al.
Publicado: (2019)

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort
por: Rofes, Paula, et al.
Publicado: (2021)

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
por: Twelves, Chris, et al.
Publicado: (2016)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
por: Yoshie, Mikihiro, et al.
Publicado: (2021)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)
por: Park, Min Ho, et al.
Publicado: (2020)

Characterisation of the rumen resistome in Spanish dairy cattle
por: López-Catalina, Adrián, et al.
Publicado: (2021)

An α-chloroaldehyde-based formal synthesis of eribulin
por: Kaghad, Anissa, et al.
Publicado: (2023)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
por: Kok, Victor C.
Publicado: (2015)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
por: Goto, Wataru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gu75h3gj943cd9tp57pis12tao